• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary pharmacology & therapeutics >Hypoxia-inducible factor-2α and refractory nsclc: Further evidence to support the use of immune-checkpoint inhibitors?
【24h】

Hypoxia-inducible factor-2α and refractory nsclc: Further evidence to support the use of immune-checkpoint inhibitors?

机译：缺氧诱导因子-2α和难治性NSCLC：进一步证明支持免疫检查点抑制剂的使用？

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hypoxia-inducible factor-2a (HIF-2α) has been suggested to be a key player in the development of cancers [1]. Over-expression of HIF-2a has been closely connected with tumor differentiation, tumor-node-metastasis (TNM) stage and lymph metastasis [1]. To date, the prognostic and pathologic significance of HIF-2a in patients with cancer remains a major concern, although still debated [1], Recently, HIF-2a has been reported to be a potential indicator of poor prognosis and clinicopathological characteristics of neoplasms to be utilized as a new effective biomarker to predict human cancer [1]. Hypoxia represents one of the most important obstacle to the effectiveness of cancer therapies [2], HIFs including HIF-2a have been found to play a critical role in controlling hypoxia-induced carcinogenic pathways by controlling the expression of a huge array of genes implicated in cancer progression and treatment resistance [2,3]. HIF-2α appears to be actively involved in the later cancer stages [3], It has been underlined that prolonged rather than short hypoxia is a hallmark of metastasis and chemoresistance that occur during the later stages of cancer [3]. Although efforts in targeting HIFs, no agents directly blocking HIFs have been approved for the treatment of patients with cancer [2]. Ligand programmed cell death (PD-L1) up-regulation has been supposed to be HIF-2α dependent [4]. It has been stated that PD-L1 relates to tumor microenvironment and HIF expression [4]. High HIF-2a expression has been strongly associated with PD-L1 expression [4].
机译：已经提出了缺氧诱导因子-2a（HIF-2α）是癌症发育中的关键球员[1]。 HIF-2a的过表达与肿瘤分化，肿瘤 - 节点转移（TNM）阶段和淋巴转离症[1]密切相关[1]。迄今为止，癌症患者HIF-2A的预后和病理意义仍然是一个主要问题，尽管仍然辩论[1]，最近，据报道，HIF-2a是潜在的指标，其肿瘤预后差和肿瘤的临床病理特征差用作新的有效生物标志物预测人类癌症[1]。缺氧是癌症治疗疗法有效性最重要的障碍之一[2]，已经发现包括HIF-2a的HIFS通过控制涉及巨大阵列的基因的表达来起到控制缺氧诱导的致癌途径中的关键作用癌症进展和治疗抗性[2,3]。 HIF-2α似乎正在积极参与后期的癌症阶段[3]，它已经强调，延长而不是短的缺氧是转移和化学抑制的标志，在癌症的后期发生[3]。尽管靶向HIF的努力，但没有直接阻断HIF的药剂已被批准用于治疗癌症患者[2]。 Ligand编程的细胞死亡（PD-L1）上调已被认为是HIF-2α取决于[4]。已经指出，PD-L1涉及肿瘤微环境和HIF表达[4]。高HIF-2A表达与PD-L1表达有牢固相关[4]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号